Erika Hamilton: Otto Metzger discusses molecular biomarkers and how we may use in HR+ bcsm

Erika Hamilton shared on X/Twitter:

“Otto Metzger discusses molecular biomarkers and how we may use in HR+ bcsm. Highlights differences in the anti-estrogens. Need to make sure pts have endocrine sensitive disease before enrolling post CDK or we risk negative trials.

(also too tall for the podium at JSMO24)”

Source: Erika Hamilton/X

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective. Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.